Quantitative proteomic analysis of serum from pregnant women carrying a fetus with conotruncal heart defect using isobaric tags for relative and absolute quantitation (iTRAQ) labeling

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Zhang, Ying ^a   Kang, Yuan ^a   Zhou, Qiongjie ^a   Zhou, Jizi ^a   Wang, Huijun ^a   Jin, Hong ^a   Liu, Xiaohui ^a   Ma, Duan ^a   Li, Xiaotian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELSOLIN; BIOLOGICAL MARKER; PLASMA PROTEIN;

ANALYTIC METHOD; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONOTRUNCAL HEART MALFORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FETUS; GESTATIONAL AGE; HEART LEFT VENTRICLE OUTFLOW TRACT; HUMAN; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION LABELING; LIQUID CHROMATOGRAPHY; MATERNAL BLOOD; MATERNAL SERUM; NUCLEOTIDE SEQUENCE; PREGNANT WOMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ADULT; BLOOD; EMBRYOLOGY; GENE EXPRESSION PROFILING; HEART DEFECTS, CONGENITAL; METABOLISM; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES;

ADULT; BIOMARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; FEMALE; GELSOLIN; GENE EXPRESSION PROFILING; HEART DEFECTS, CONGENITAL; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84911920411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111645     Document Type: Article

References (56)

1. Shaw GM, Carmichael SL, Yang W, Lammer EJ (2010) Periconceptional nutrient intakes and risks of conotruncal heart defects. Birth Defects Res A Clin Mol Teratol 88: 144-151.
2. Botto LD, Correa A, Erickson JD (2001) Racial and temporal variations in the prevalence of heart defects. Pediatrics 107: E32.
3. Centers for Disease Control and Prevention (CDC) (1998) Trends in infant mortality attributable to birth defects-United States, 1980-1995. MMWR Morb Mortal Wkly Rep 47: 773-778.
4. Benson DW, Basson CT, MacRae CA (1996) New understandings in the genetics of congenital heart disease. Curr Opin Pediatr 8: 505-511.
5. Pierpont ME, Basson CT, Benson DW Jr., Gelb BD, Giglia TM, et al. (2007) Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115: 3015-3038.
6. Ratajska A, Ciszek B, Zajaczkowska A, Jablonska A, Juszynski M (2009) Angioarchitecture of the venous and capillary system in heart defects induced by retinoic acid in mice. Birth Defects Res A Clin Mol Teratol 85: 599-610.
7. Lisowski LA, Verheijen PM, Copel JA, Kleinman CS, Wassink S, et al. (2010) Congenital heart disease in pregnancies complicated by maternal diabetes mellitus. An international clinical collaboration, literature review, and metaanalysis. Herz 35: 19-26.
8. van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH, Kouwenberg M, et al. (2006) Maternal MTHFR 677C .T is a risk factor for congenital heart defects: effect modification by periconceptional folate supplementation. Eur Heart J 27: 981-987.
9. Debrus S, Berger G, de Meeus A, Sauer U, Guillaumont S, et al. (1996) Familial non-syndromic conotruncal defects are not associated with a 22q11 microdeletion. Hum Genet 97: 138-144.
10. Hoffman JI, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39: 1890-1900.
11. Galindo A, Mendoza A, Arbues J, Graneras A, Escribano D, et al. (2009) Conotruncal anomalies in fetal life: accuracy of diagnosis, associated defects and outcome. Eur J Obstet Gynecol Reprod Biol 146: 55-60.
12. Hutson MR, Kirby ML (2003) Neural crest and cardiovascular development: a 20-year perspective. Birth Defects Res C Embryo Today 69: 2-13.
13. Kirby ML, Waldo KL (1995) Neural crest and cardiovascular patterning. Circ Res 77: 211-215.
14. Clark EB (1996) Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Semin Perinatol 20: 465-472.
15. Long J, Ramadhani T, Mitchell LE (2010) Epidemiology of nonsyndromic conotruncal heart defects in Texas, 1999-2004. Birth Defects Res A Clin Mol Teratol 88: 971-979.
16. Kolialexi A, Tsangaris GT, Papantoniou N, Anagnostopoulos AK, Vougas K, et al. (2008) Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenat Diagn 28: 691-698.
17. Park SJ, Yoon WG, Song JS, Jung HS, Kim CJ, et al. (2006) Proteome analysis of human amnion and amniotic fluid by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proteomics 6: 349-363.
18. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE (1984) An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148: 886-894.
19. Wald NJ, Kennard A, Hackshaw A, McGuire A (1997) Antenatal screening for Down's syndrome. J Med Screen 4: 181-246.
20. Zhang X, Yin X, Yu H, Liu X, Yang F, et al. (2012) Quantitative proteomic analysis of serum proteins in patients with Parkinson's disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Analyst 137: 490-495.
21. Huang Z, Wang H, Huang H, Xia L, Chen C, et al. (2012) iTRAQ-based proteomic profiling of human serum reveals down-regulation of platelet basic protein and apolipoprotein B100 in patients with hematotoxicity induced by chronic occupational benzene exposure. Toxicology 291: 56-64.
22. Kang Y, Dong X, Zhou Q, Zhang Y, Cheng Y, et al. (2012) Identification of novel candidate maternal serum protein markers for Down syndrome by integrated proteomic and bioinformatic analysis. Prenat Diagn 32: 284-292.
23. Kolla V, Jeno P, Moes S, Tercanli S, Lapaire O, et al. (2010) Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J Biomed Biotechnol 2010: 952047.
24. Wang TH, Chao AS, Chen JK, Chao A, Chang YL, et al. (2009) Network analyses of differentially expressed proteins in amniotic fluid supernatant associated with abnormal human karyotypes. Fertil Steril 92: 96-107.
25. Kolialexi A, Anagnostopoulos AK, Papantoniou N, Vougas K, Antsaklis A, et al. (2010) Potential biomarkers for Turner in maternal plasma: possibility for noninvasive prenatal diagnosis. J Proteome Res 9: 5164-5170.
26. Mavrou A, Anagnostopoulos AK, Kolialexi A, Vougas K, Papantoniou N, et al. (2008) Proteomic analysis of amniotic fluid in pregnancies with Turner syndrome fetuses. J Proteome Res 7: 1862-1866.
27. Anagnostopoulos AK, Kolialexi A, Mavrou A, Vougas K, Papantoniou N, et al. (2010) Proteomic analysis of amniotic fluid in pregnancies with Klinefelter syndrome foetuses. J Proteomics 73: 943-950.
28. Cecconi D, Lonardoni F, Favretto D, Cosmi E, Tucci M, et al. (2011) Changes in amniotic fluid and umbilical cord serum proteomic profiles of foetuses with intrauterine growth retardation. Electrophoresis 32: 3630-3637.
29. Auer J, Camoin L, Guillonneau F, Rigourd V, Chelbi ST, et al. (2010) Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteomics 73: 1004-1017.
30. Park J, Cha DH, Lee SJ, Kim YN, Kim YH, et al. (2011) Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp Mol Med 43: 427-435.
31. Esplin MS, Merrell K, Goldenberg R, Lai Y, Iams JD, et al. (2011) Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol 204: 391 e391-398.
32. Gercel-Taylor C, Taylor DD, Rai SN (2012) Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol 206: e3; author reply e3-4.
33. Gravett MG, Novy MJ, Rosenfeld RG, Reddy AP, Jacob T, et al. (2004) Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 292: 462-469.
34. Datta A, Qian J, Chong R, Kalaria RN, Francis P, et al. (2014) Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. J Proteomics 99: 54-67.
35. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
36. Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW (2012) The usefulness of brain natriuretic peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol 60: 2140-2149.
37. Cantinotti M, Giovannini S, Murzi B, Clerico A (2011) Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases. Clin Chem Lab Med 49: 567-580.
38. Nir A, Luchner A, Rein AJ (2012) The natriuretic peptides as biomarkers for adults with congenital heart disease. Biomark Med 6: 827-837.
39. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, et al. (2005) Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 41: 461-469.
40. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, et al. (2001) Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 65: 11-21.
41. Gay F, Estornes Y, Saurin JC, Joly-Pharaboz MO, Friederich E, et al. (2008) In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol 39: 1420-1430.
42. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ (1999) Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 40: 14-19.
43. Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, et al. (2011) Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance. Gynecol Oncol 120: 135-144.
44. Xianhui L, Pinglian L, Xiaojuan W, Wei C, Yong Y, et al. (2014) The association between plasma gelsolin level and prognosis of burn patients. Burns.
45. Cohen TS, Bucki R, Byfield FJ, Ciccarelli NJ, Rosenberg B, et al. (2011) Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine 54: 235-238.
46. Jin Y, Li BY, Qiu LL, Ling YR, Bai ZQ (2012) Decreased plasma gelsolin is associated with 1-year outcome in patients with traumatic brain injury. J Crit Care 27: 527 e521-526.
47. Xu JF, Liu WG, Dong XQ, Yang SB, Fan J (2012) Change in plasma gelsolin level after traumatic brain injury. J Trauma Acute Care Surg 72: 491-496.
48. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, et al. (2000) Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102: 3046-3052.
49. Mani SK, Shiraishi H, Balasubramanian S, Yamane K, Chellaiah M, et al. (2008) In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol 295: H314-326.
50. Hu WS, Ho TJ, Pai P, Chung LC, Kuo CH, et al. (2014) Gelsolin (GSN) induces cardiomyocyte hypertrophy and BNP expression via p38 signaling and GATA-4 transcriptional factor activation. Mol Cell Biochem 390: 263-270.
51. Sezen D, Bongiovanni AM, Gelber S, Perni U, Hutson JM, et al. (2009) Gelsolin down-regulates lipopolysaccharide-induced intraamniotic tumor necrosis factoralpha production in the midtrimester of pregnancy. Am J Obstet Gynecol 200: 191 e191-194.
52. Scholl PF, Cole RN, Ruczinski I, Gucek M, Diez R, et al. (2012) Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal. Placenta 33: 424-432.
53. Xuan C, Gao G, Yang Q, Wang XL, Liu ZG, et al. (2014) Proteomic study reveals plasma protein changes in congenital heart diseases. Ann Thorac Surg 97: 1414-1419.
54. Plageman TF, Jr., Yutzey KE (2006) Microarray analysis of Tbx5-induced genes expressed in the developing heart. Dev Dyn 235: 2868-2880.
55. Gardiner HM (2001) Fetal echocardiography: 20 years of progress. Heart 86 Suppl 2: II12-22.
56. Buskens E, Stewart PA, Hess J, Grobbee DE, Wladimiroff JW (1996) Efficacy of fetal echocardiography and yield by risk category. Obstet Gynecol 87: 423-428.